地加瑞克治疗前列腺癌可降低心血管事件风险

近日在意大利米兰召开的欧洲泌尿外科协会会议上，研究人员发布了一项前列腺癌的研究成果：与其他前列腺治疗药物相比，地加瑞克（Firmagon或degarelix）可降低心血管事件的风险。

来自比利时法语区鲁汶大学的Bertrand Tombal和来自德国柏林本杰明•富兰克林医疗中心的Kurt Miller进行了该项研究，他们称研究数据显示，与常规处方药促黄体生成素释放激素激动剂相比，地加瑞克（Firmagon或degarelix）能显著性降低心血管事件的风险，而前者往往导致男性患者睾酮水平下降。

对于存在心血管疾病的男性来说，结果显示，与接受促黄体生成素释放激素激动剂的患者相比，接受地加瑞克治疗使前列腺癌患者后期心脏病、中风等心血管疾病风险以及死亡风险降低了50%以上。数据来源于2328例不同国家的前列腺癌患者的荟萃分析。

研究还发现，与接受促黄体生成素释放激素激动剂相比，接受地加瑞克治疗的患者，总体生存率明显上升，前列腺癌的症状控制得到改善，骨折概率降低，肾脏以及泌尿系统的不良反应减少。研究表明，与常见的可能引起男性体内睾丸激素水平下降的黄体激素释放激素激动剂相比，地加瑞克可显著降低心血管事件的风险。

与心血管相关的拓展阅读：

• Diabetes Care：维生素D缺乏不能预测糖尿病患者心血管风险
• JAMA:高灵敏度cTnT与二级预防的心血管事件相关
• 心血管领域临床进展及SCI论文和基金写作-MedSci快报（第72期）
• Sirtuins---在心血管系统的作用全面解析
• Diabetes Care：低血糖症增加心血管事件风险
• Nat Rev Cardiol：戒烟降低非糖尿病患者心血管疾病风险
更多信息请点击：有关心血管更多资讯

Less-risky prostate cancer therapy offered
MILAN, Italy, March 16 (UPI) -- Data shows lower cardiovascular risk with Firmagon, a hormonal therapy for prostate cancer, compared with other prostate treatments, European researchers say.
Bertrand Tombal of Universite Catholique de Louvain in Brussels and Kurt Miller of the Benjamin Franklin Medical Center in Berlin said the data suggested a significantly lower risk of cardiovascular events with Firmagon, or degarelix, compared with commonly prescribed luteinising hormone-releasing hormone agonists -- which causes testosterone levels to fall in men.
In men with existing cardiovascular disease, there was more than 50 percent less chance of a subsequent cardiovascular event -- heart attack or stroke -- or death with Firmagon when compared with men receiving luteinising hormone-releasing hormone agonists.
The data involved 2,328 patients in different countries pooled for study analysis.
The pooled analysis also showed men treated with Firmagon had significantly higher overall survival and improved disease control -- fewer fractures and a lower incidence of renal or urinary tract adverse events when compared with luteinising hormone-releasing hormone agonists.
The findings are being presented at the European Association of Urology in Milan, Italy.